CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PTC Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PTC Therapeutics, Inc.
500 Warren Corporate Center Drive
Phone: (908) 222-7000p:908 222-7000 WARREN, NJ  07059  United States Ticker: PTCTPTCT
Business Summary
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board MichaelSchmertzler 71 11/1/2004 8/1/2001
President, Chief Executive Officer, Director Matthew B.Klein 51 3/22/2023 4/17/2020
Chief Financial Officer PierreGravier 39 7/13/2023 7/13/2023
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BioElectron Technology Corporation 350 Bernardo Ave. Mountain View CA United States

Business Names
Business Name
Agilis Biotherapeutics, Inc.
BioElectron Technology Corporation
Censa Pharmaceuticals Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 988 (As of 12/31/2023)
Outstanding Shares: 76,608,030 (As of 2/27/2024)
Shareholders: 98
Stock Exchange: NASD
Federal Tax Id: 043416587
Fax Number: (908) 222-7231
Email Address: info@ptcbio.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024